BA
NBIX icon

Bristlecone Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Bristlecone Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,779
Closed -$379K – 386
2024
Q4 		$379K Sell
2,779
-76
-3% -$9.4K 0.03% 218
2024
Q3 		$329K Sell
2,855
-30
-1% -$4.11K 0.03% 231
2024
Q2 		$397K Sell
2,885
-95
-3% -$13K 0.03% 201
2024
Q1 		$411K Sell
2,980
-15
-0.5% -$2.05K 0.04% 199
2023
Q4 		$395K Sell
2,995
-154
-5% -$17.7K 0.04% 199
2023
Q3 		$354K Hold
3,149
– – 0.04% 195
2023
Q2 		$297K Sell
3,149
-292
-8% -$28.5K 0.03% 220
2023
Q1 		$348K Sell
3,441
-251
-7% -$26.1K 0.04% 203
2022
Q4 		$441K Hold
3,692
– – 0.05% 184
2022
Q3 		$392K Buy
3,692
+32
+0.9% +$3.25K 0.05% 181
2022
Q2 		$357K Sell
3,660
-2,189
-37% -$202K 0.04% 192
2022
Q1 		$548K Buy
5,849
+898
+18% +$76.1K 0.07% 152
2021
Q4 		$422K Buy
4,951
+1,181
+31% +$109K 0.05% 172
2021
Q3 		$362K Buy
3,770
+444
+13% +$41.9K 0.05% 170
2021
Q2 		$324K Buy
3,326
+85
+3% +$8.15K 0.04% 175
2021
Q1 		$315K Buy
3,241
+675
+26% +$70.8K 0.05% 176
2020
Q4 		$246K Buy
+2,566
New +$248K 0.04% 183

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bristlecone Advisors's NBIX Position: Q1 2025 in Review

Bristlecone Advisors sold out of Neurocrine Biosciences (NBIX) in Q1 2025, closing a stake of 2,779 shares — an estimated $379K sold.

Bristlecone Advisors first reported a position in NBIX in Q4 2020 and held it in 17 quarters. The position peaked at $548K in Q1 2022. 586 funds tracked by Wall St. Rank hold NBIX as of Q1 2025.

  • Bristlecone Advisors reported no remaining Neurocrine Biosciences position as of Q1 2025 after selling out during the quarter.
  • Bristlecone Advisors sold 2,779 Neurocrine Biosciences shares in Q1 2025, an estimated $379K.
  • Bristlecone Advisors first reported a position in Neurocrine Biosciences in Q4 2020 and held it in 17 quarters.
  • Bristlecone Advisors's Neurocrine Biosciences position peaked at $548K in Q1 2022.
  • 586 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2025.

Based on Bristlecone Advisors's 13F filing for Q1 2025, filed 12 May 2025.